Floatz logo

Apixaban

Atrial Fibrillation

Regeneron PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Atrial Fibrillation cohort.

Asset / SponsorPhaseRating
Edoxaban
National Taiwan University Hospital
Phase 4A
Rivaroxaban
VA Office of Research and Development
Phase 4BBB
Dabigatran
Pfizer
Phase 4BBB
WARFARIN
Pfizer
Phase 4BBB
Acetylsalicylic Acid
Yonsei University
Phase 4BBB

View all 40 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →